USPTO serial 79420492
CHO.SET LIBRARY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 10, 2026
- Examiner
- NODES, CHRISTOPHER JAMES
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with CHO.SET LIBRARY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Steven J. Solomon
Steven J. Solomon Tucker Ellis LLP950 Main Avenue, Suite 1100Cleveland, OH 44113United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Proteins for use in recombinant DNA technology other than for medical use; synthetic promoters for gene expression for scientific, research, or manufacturing purposes; enzymes other than for medical use for use in the continuous homogenous isothermal amplifications of specific DNA templates; enzymes for detecting protein fractions other than for medical use; proteins for binding antibodies other than for medical or veterinary use; chemical preparations for use in DNA analysis other than medical or veterinary use; enzymes for use in detecting proteins other than for medical or veterinary use; enzymes other than for medical use for use in the continuous homogenous isothermal amplifications of specific MA templates; nucleic acid sequencing programs, namely, DNA and RNA which have imbedded programs in the nature of nucleotide sequences which direct cellular processes, other than for medical or veterinary use; enzymes for labelling protein fractions other than for medical use; nucleic recombinant acids other than for medical or veterinary purposes; enzymes for measuring proteins other than for medical use; synthetic promoters for gene expression for scientific, research or manufacturing purposes, namely, for use in the production of secreted proteins by cell culture for use in oncology indications, reproductive indications, autoimmune diseases, blood diseases, inborn errors of metabolism, infection by pathogenic bacteria and viruses, hormone related disease, bone injuries. | ACTIVE | — |
| 005 | Biopharmaceutical preparations for use in oncology and reproductive indications, and to treat autoimmune diseases, blood diseases, in-born errors of metabolism, infection by pathogenic bacteria and viruses, hormone related disease, bone injuries; protein synthesis inhibitors for use in oncology and reproductive indications, and to treat autoimmune diseases, blood diseases, in-born errors of metabolism, infection by pathogenic bacteria and viruses, hormone related disease, bone injuries; human plasma protein for use in oncology and reproductive indications, and to treat autoimmune diseases, blood diseases, in-born errors of metabolism, infection by pathogenic bacteria and viruses, hormone related disease, bone injuries; blood protein fractions for the treatment or prevention of shock, for treatment of burns, trauma, hypoalbuminemia, liver failure, ascites management, immune deficiencies, immunodeficiency, autoimmune diseases, passive immunity against specific pathogens, namely, tetanus immune globulin, rabies immune globulin; blood protein fractions for coagulation for the treatment of haemophilia, Von Willebrand disease, fibrinogen deficiency, bleeding disorders; blood protein fractions for fibrinogen and thrombin to promote clot formation, reduce bleeding and to aid wound closure; blood protein fractions for diagnostic applications for antibodies for assays; endogenous antigens for use in oncology and reproductive indications, and to treat autoimmune diseases, blood diseases, in-born errors of metabolism, infection by pathogenic bacteria and viruses, hormone related disease, bone injuries; exogenous antigens for use as vaccines; DNA synthesis inhibitors for use in oncology and reproductive indications, and to treat autoimmune diseases, blood diseases, in-born errors of metabolism, infection by pathogenic bacteria and viruses, hormone related disease, bone injuries; antibodies for medical purposes; regulatory proteins for medical use for use in oncology and reproductive indications, and to treat autoimmune diseases, blood diseases, in-born errors of metabolism, infection by pathogenic bacteria and viruses, hormone related disease, bone injuries; RNA synthesis inhibitors for use in oncology and reproductive indications, and to treat autoimmune diseases, blood diseases, in-born errors of metabolism, infection by pathogenic bacteria and viruses, hormone related disease, bone injuries; mRNA vaccines; synthetic peptides for pharmaceutical purposes for use in oncology and reproductive indications, and to treat autoimmune diseases, blood diseases, in-born errors of metabolism, infection by pathogenic bacteria and viruses, hormone related disease, bone injuries; antigens for use in oncology and reproductive indications, and to treat autoimmune diseases, blood diseases, in-born errors of metabolism, infection by pathogenic bacteria and viruses, hormone related disease, bone injuries }; mycolic acid synthesis inhibitors for the treatment of mycobacterial infections, tuberculosis and leprosy and to support treatment of drug resistant tuberculosis; preparations for detecting mutation in prion genes for medical purposes; viral antigens for use in oncology and reproductive indications, and to treat autoimmune diseases, blood diseases, in-born errors of metabolism, infection by pathogenic bacteria and viruses, hormone related disease, bone injuries; hormone preparations for use in oncology and reproductive indications, and to treat autoimmune diseases, blood diseases, in-born errors of metabolism, infection by pathogenic bacteria and viruses, hormone related disease, bone injuries; viral vaccines; human vaccine preparations; AAV viral vector and recombinant protein for use in oncology and reproductive indications, and to treat autoimmune diseases, blood diseases, in-born errors of metabolism, infection by pathogenic bacteria and viruses, hormone related disease, bone injuries; genetic vectors for use in oncology and reproductive indications, and to treat autoimmune diseases, blood diseases, in-born errors of metabolism, infection by pathogenic bacteria and viruses, hormone related disease, bone injuries; chemical preparations for use in DNA analysis for medical purposes; therapeutic DNA and mRNA for use in oncology and reproductive indications, and to treat autoimmune diseases, blood diseases, in-born errors of metabolism, infection by pathogenic bacteria and viruses, hormone related disease, bone injuries. | ACTIVE | — |
| 035 | Collection of information into computer databases, particularly commercial, scientific, health, gene and cell information; collection of data into computer databases, particularly commercial, scientific, health, gene and cell data; computerized database management; computerized file management; management of files and records related to the health status of individuals, molecules and formulation for medical use, as well as medicines and medical research; management of computerized files, namely, data retrieval services; statistical information compilation services into computer databases; data processing services; data processing via computer; management of computer files and data stored in electronic format, on hardware, and in products for medical and non-medical research and analysis; management of computerized files, namely, collating and maintaining computer files and data in electronic format, in the field of materials and products for medical and non-medical research and analysis; promoting the services of others by the bringing together, for third parties, of service offers relating to capture, collection, analysis, processing and use of data, particularly medical, health gene and cell research data; computerized database management services, namely, data capture, collection of data, particularly health, gene and cell data; data processing services, namely, processing of data, particularly health, gene and cell data; data analysis for business purposes and use of data being data analysis for business purposes, particularly health, gene and cell data; information and advice concerning all the aforesaid services; all the aforesaid services provided in connection with or relating to scientific research and the medical field; compilation of scientific and technical information into computer databases; compilation of information into computer databases related to people's health, to medicines in the nature of medical information and to gene and cell therapy; compilation of medical reports, medical prescriptions and recommendations in the nature of medical information into computer databases; information and advice concerning all the aforesaid services. | ACTIVE | — |
| 042 | Structural and functional analysis of genomes; genetic fingerprinting; genetic research; research in the field of gene therapy; laboratory research in the field of gene expression; analysis in the field of molecular biology for research purposes; biochemical analysis for research purposes; research and development services in the field of gene expression systems; research and development services in the field of genes and cells; biotechnology research; scientific research in the field of genetics and genetic engineering; biological analysis for research purposes; genetic mapping for scientific purposes; genetic engineering services; biotechnology testing, namely, testing in the field of biopharmaceutical development; biochemical research and development; scientific and technical analysis and research in the field of biotechnology; computer testing and analysis, namely, testing and analysis of computer systems; quality control for others and auditing in the nature technical analysis and evaluation of manufacturing processes for others; quality control of software, scientific and technical data and scientific and technical analyses; design of technical and scientific studies; design, development, programming, configuration, installation, maintenance, updating and testing of algorithms and software, particularly for artificial intelligence and decision support systems; design, development, programming, configuration, installation, maintenance, updating and testing of algorithms and computer software and platforms for consulting, analyzing, exchanging and sharing data, particularly in a collaborative work environment; scientific research in the field of design, development, formulation, updating in the nature of developing and testing of new medicines and new medicine formulas; quality control for others in the nature of evaluation of the performance of medical treatments; design and development, including selection and training, of models and software for gene and cell therapy; software as a service (SAAS) services featuring software for the remote provision of models for gene and cell therapy; software as a service (SAAS) services featuring software platforms for data collection, management, analysis, modelling, and sharing, and for managing laboratory workflows and research processes in the field of gene and cell therapy research and production of proteins in mammalian cells using recombinant DNA technology; software as a service (SAAS) services featuring software for data input, extraction, processing, display and storage relating to gene and cell therapy; provision of information relating to scientific technology; provision of temporary use of non-downloadable software for data processing and analysis relating to gene and cell therapy; technical writing, namely, preparation of technical and scientific manuals; technical writing, namely, preparation of technical and scientific reports; technology research in the field of biotechnology, biopharmaceuticals, gene and cell therapy; scientific research services; data analysis computer services, namely, providing temporary use of non-downloadable computer software for data analysis; computer programming services for data analysis and interpretation relating to gene and cell therapy; information and advice concerning all the aforesaid services; all the aforesaid services provided in connection with or relating to scientific research and the medical field; stem cell research services; stem cell research; advisory services relating to gene therapy research; cell separation technology research services; cell separation research services; biotechnology research for determining the neuronal survival of molecules in animal models; biological cloning services; research and development of vaccines and medicines; laboratory services relating to the production of monoclonal antibodies; research in the field of cell therapy. | ACTIVE | — |
| 044 | Medical analysis for diagnosis and treatment of persons; medical, gene and cell data analysis for diagnosis and treatment of persons; medical analysis services relating to the treatment of persons, namely, conducting of studies and analyses on health of persons, medicines for medical diagnostic and treatment purposes and for gene and cell therapy; medical screening; medical advisory services, namely, preparation of medical reports and medical recommendations; carrying out disease diagnostics; advisory services in the field of health care, and medical services in the nature of gene and cell therapy; medical diagnosis services; stem cell therapy services; cell bank and tissue bank services in the nature of stem cell storage; stem cell bank services; cultured cell bank services for medical transplantation; medical treatment using cultured cells; RNA and DNA analysis for cancer diagnosis and prognosis; medical services relating to the removal, treatment and processing of human genes and cells for the diagnosis and treatment of persons; information and advice concerning all the aforesaid services. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SYNGENSYS LIMITED
- Other trademarks owned by SYNGENSYS LIMITED
- Other trademarks owned by SYNGENSYS LIMITED
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CHO.SET LIBRARY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 10, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 10, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 22, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 22, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 17, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 16, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 2, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 2, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Aug 27, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 26, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 26, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 26, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Aug 26, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 26, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 26, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Feb 26, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 26, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 26, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 29, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 29, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 29, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 23, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 2, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 2, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 11, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 10, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 5, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 4, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 4, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 3, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |